Jun 24, 2026
Brazilian researchers developed a CT-based biomarker called VMD that combines visceral fat and muscle radiodensity to predict gastric cancer prognosis, with patient survival ranging from 13.8 to 58.5 months. The global PET imaging market is projected to grow to $1.4 billion by 2032 as cancer cases rise globally. Neuroendocrine tumor research is advancing with new funding and studies on Hedgehog signaling pathways.
Jun 11, 2026
The global oncology drugs market is projected to grow at an 8-10% CAGR through 2035 as targeted therapies and immunotherapies gain share over chemotherapy. The radiopharmaceuticals market is expected to reach $21.8 billion by 2033, fueled by rising cancer incidence and expanding diagnostic and therapeutic applications. Innovations in drug delivery, including intranasal platforms for glioblastoma, are advancing neuro-oncology treatment options.
May 04, 2026
The radioligand therapeutics market in cancer treatment is estimated to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at a 13.1% CAGR. Growth is supported by approved products Pluvicto and Lutathera and expanding use of PSMA and SSTR-targeted therapies.
Apr 18, 2026
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
Apr 11, 2026
Cabozantinib plus metronomic temozolomide showed a 15% response rate and 28.5-month median progression-free survival in a phase 2 NET study. A separate analysis found cabozantinib cost-effective for pancreatic NETs, but not extrapancreatic NETs, in China and the U.S.
Mar 12, 2026
The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.
Feb 14, 2026
Researchers have developed modified CAR T cells that overcome prostaglandin E2 suppression in solid tumors and a selective therapy targeting IGHV4-34 that spares healthy immune cells, addressing key limitations in current treatments.
